Concerted down-regulation of immune-system related genes predicts metastasis in colorectal carcinoma

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Fehlker, Marion ^a   Huska, Matthew R ^b,c   Jöns, Thomas ^a   Andrade Navarro, Miguel A ^b   Kemmner, Wolfgang ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

Author keywords

Computational marker analysis; Early colorectal cancer; Gene expression profiling; Immune system; Metastasis

Indexed keywords

AGED; CARCINOMA; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS II; HUMANS; MALE; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893183937     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-64     Document Type: Article

References (50)

1. Union E. Europe against Colorectal Cancer, Declaration of Brussels 2007, European Union: Brussels.
2. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009, 361:2449-2460. 10.1056/NEJMra0804588, 2843693, 20018966.
3. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. Lancet 2010, 375:1030-1047. 10.1016/S0140-6736(10)60353-4, 20304247.
4. Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004, 22:1564-1571. 10.1200/JCO.2004.08.186, 15051756.
5. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhoffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005, 23:3526-3535. 10.1200/JCO.2005.00.695, 15908663.
6. Arango D, Laiho P, Kokko A, Alhopuro P, Sammalkorpi H, Salovaara R, Nicorici D, Hautaniemi S, Alazzouzi H, Mecklin JP, Jarvinen H, Hemminki A, Astola J, Schwartz S, Aaltonen LA. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology 2005, 129:874-884. 10.1053/j.gastro.2005.06.066, 16143127.
7. Pillaire MJ, Selves J, Gordien K, Gourraud PA, Gentil C, Danjoux M, Do C, Negre V, Bieth A, Guimbaud R, Trouche D, Pasero P, Mechali M, Hoffmann JS, Cazaux C. A 'DNA replication' signature of progression and negative outcome in colorectal cancer. Oncogene 2010, 29:876-887. 10.1038/onc.2009.378, 19901968.
8. Jorissen RN, Gibbs P, Christie M, Prakash S, Lipton L, Desai J, Kerr D, Aaltonen LA, Arango D, Kruhoffer M, Orntoft TF, Andersen CL, Gruidl M, Kamath VP, Eschrich S, Yeatman TJ, Sieber OM. Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clin Cancer Res 2009, 15:7642-7651. 10.1158/1078-0432.CCR-09-1431, 2920750, 19996206.
9. Barrier A, Lemoine A, Boelle PY, Tse C, Brault D, Chiappini F, Breittschneider J, Lacaine F, Houry S, Huguier M, Van der Laan MJ, Speed T, Debuire B, Flahault A, Dudoit S. Colon cancer prognosis prediction by gene expression profiling. Oncogene 2005, 24:6155-6164. 10.1038/sj.onc.1208984, 16091735.
10. Barrier A, Boelle PY, Roser F, Gregg J, Tse C, Brault D, Lacaine F, Houry S, Huguier M, Franc B, Flahault A, Lemoine A, Dudoit S. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006, 24:4685-4691. 10.1200/JCO.2005.05.0229, 16966692.
11. Zhang X, Lu X, Shi Q, Xu XQ, Leung HC, Harris LN, Iglehart JD, Miron A, Liu JS, Wong WH. Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics 2006, 7:197. 10.1186/1471-2105-7-197, 1456993, 16606446.
12. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001, 98:5116-5121. 10.1073/pnas.091062498, 33173, 11309499.
13. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80. 10.1186/gb-2004-5-10-r80, 545600, 15461798.
14. Huber W, von Heydebreck A, Sueltmann H, Poustka A, Vingron M. Parameter estimation for the calibration and variance stabilization of microarray data. Stat Appl Genet Mol Biol 2003, 2:Article3.
15. Kauffmann A, Gentleman R, Huber W. arrayQualityMetrics-a bioconductor package for quality assessment of microarray data. Bioinformatics 2009, 25:415-416. 10.1093/bioinformatics/btn647, 2639074, 19106121.
16. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001, 125:279-284. 10.1016/S0166-4328(01)00297-2, 11682119.
17. Falcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007, 23:257-258. 10.1093/bioinformatics/btl567, 17098774.
18. Astrosini C, Roeefzaad C, Dai YY, Dieckgraefe BK, Jons T, Kemmner W. REG1A expression is a prognostic marker in colorectal cancer and associated with peritoneal carcinomatosis. Int J Cancer 2008, 123:409-413. 10.1002/ijc.23466, 18452172.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
20. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50:113-130. 10.1111/j.1365-2559.2006.02549.x, 17204026.
21. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M, Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257. 10.1056/NEJMoa022289, 3584639, 12867608.
22. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964. 10.1126/science.1129139, 17008531.
23. Salama P, Platell C. Host response to colorectal cancer. ANZ J Surg 2008, 78:745-753. 10.1111/j.1445-2197.2008.04642.x, 18844901.
24. Kishimoto T, Saito K, Ishikura H. [Mechanism of blood-borne metastasis in relation to the interaction between pancreatic carcinoma and endothelial cells]. Nippon Rinsho 1995, 53:1765-1769.
25. Koda K, Saito N, Takiguchi N, Oda K, Nunomura M, Nakajima N. Preoperative natural killer cell activity: correlation with distant metastases in curatively research colorectal carcinomas. Int Surg 1997, 82:190-193.
26. Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, van de Velde CJ, van Krieken JH. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-a histopathological and immunohistochemical study. BMC Cancer 2001, 1:7. 10.1186/1471-2407-1-7, 35356, 11481031.
27. Nielsen HJ, Hansen U, Christensen IJ, Reimert CM, Brunner N, Moesgaard F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol 1999, 189:487-495. 10.1002/(SICI)1096-9896(199912)189:4<487::AID-PATH484>3.0.CO;2-I, 10629548.
28. Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF, McArdle CS. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 2005, 92:651-654. 10.1038/sj.bjc.6602419, 2361875, 15700032.
29. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005, 353:2654-2666. 10.1056/NEJMoa051424, 16371631.
30. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998. 10.1038/ni1102-991, 12407406.
31. Kloor M, Michel S. Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer 2010, 127:1001-1010. 10.1002/ijc.25283, 20198617.
32. Lovig T, Andersen SN, Thorstensen L, Diep CB, Meling GI, Lothe RA, Rognum TO. Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br J Cancer 2002, 87:756-762. 10.1038/sj.bjc.6600507, 2364272, 12232760.
33. Bustin SA, Li SR, Phillips S, Dorudi S. Expression of HLA class II in colorectal cancer: evidence for enhanced immunogenicity of microsatellite-instability-positive tumours. Tumour Biol 2001, 22:294-298. 10.1159/000050630, 11553859.
34. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54.
35. Matoba K, Iizuka N, Gondo T, Ishihara T, Yamada-Okabe H, Tamesa T, Takemoto N, Hashimoto K, Sakamoto K, Miyamoto T, Uchimura S, Hamamoto Y, Oka M. Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int J Cancer 2005, 115:231-240. 10.1002/ijc.20860, 15688398.
36. Network CGA. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525. 10.1038/nature11404, 3466113, 22960745.
37. Van Gool SW, Vandenberghe P, De BM, Ceuppens JL. CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev 1996, 153:47-83. 10.1111/j.1600-065X.1996.tb00920.x, 9010719.
38. Kodelja V, Muller C, Politz O, Hakij N, Orfanos CE, Goerdt S. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 1998, 160:1411-1418.
39. Leung SY, Yuen ST, Chu KM, Mathy JA, Li R, Chan AS, Law S, Wong J, Chen X, So S. Expression profiling identifies chemokine (C-C motif) ligand 18 as an independent prognostic indicator in gastric cancer. Gastroenterology 2004, 127:457-469. 10.1053/j.gastro.2004.05.031, 15300578.
40. Schutyser E, Richmond A, Van-Damme J. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol 2005, 78:14-26. 10.1189/jlb.1204712, 2665283, 15784687.
41. Sun B, Nishihira J, Yoshiki T, Kondo M, Sato Y, Sasaki F, Todo S. Macrophage migration inhibitory factor promotes tumor invasion and metastasis via the Rho-dependent pathway. Clin Cancer Res 2005, 11:1050-1058.
42. Brandacher G, Perathoner A, Ladurner R, Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G, Weiss HG, Gobel G, Margreiter R, Konigsrainer A, Fuchs D, Amberger A. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin Cancer Res 2006, 12:1144-1151. 10.1158/1078-0432.CCR-05-1966, 16489067.
43. Ishio T, Goto S, Tahara K, Tone S, Kawano K, Kitano S. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol Hepatol 2004, 19:319-326. 10.1111/j.1440-1746.2003.03259.x, 14748880.
44. Riesenberg R, Weiler C, Spring O, Eder M, Buchner A, Popp T, Castro M, Kammerer R, Takikawa O, Hatz RA, Stief CG, Hofstetter A, Zimmermann W. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin Cancer Res 2007, 13:6993-7002. 10.1158/1078-0432.CCR-07-0942, 18056175.
45. Lob S, Konigsrainer A, Rammensee HG, Opelz G, Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?. Nat Rev Cancer 2009, 9:445-452. 10.1038/nrc2639, 19461669.
46. Lin YH, Friederichs J, Black MA, Mages J, Rosenberg R, Guilford PJ, Phillips V, Thompson-Fawcett M, Kasabov N, Toro T, Merrie AE, van Rij A, Yoon HS, McCall JL, Siewert JR, Holzmann B, Reeve AE. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res 2007, 13:498-507. 10.1158/1078-0432.CCR-05-2734, 17255271.
47. Mlecnik B, Tosolini M, Charoentong P, Kirilovsky A, Bindea G, Berger A, Camus M, Gillard M, Bruneval P, Fridman WH, Pages F, Trajanoski Z, Galon J. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010, 138:1429-1440. 10.1053/j.gastro.2009.10.057, 19909745.
48. Specht K, Harbeck N, Smida J, Annecke K, Reich U, Naehrig J, Langer R, Mages J, Busch R, Kruse E, Klein-Hitpass L, Schmitt M, Kiechle M, Hoefler H. Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy. Breast Cancer Res Treat 2008, 118:45-56.
49. Michielsen AJ, Noonan S, Martin P, Tosetto M, Marry J, Biniecka M, Maguire AA, Hyland JM, Sheahan KD, O'Donoghue DP, Mulcahy HE, Fennelly D, Ryan EJ, O'Sullivan JN. Inhibition of dendritic cell maturation by the tumor microenvironment correlates with the survival of colorectal cancer patients following bevacizumab treatment. Mol Cancer Ther 2012, 11:1829-1837. 10.1158/1535-7163.MCT-12-0162, 22675042.
50. Michielsen AJ, Hogan AE, Marry J, Tosetto M, Cox F, Hyland JM, Sheahan KD, O'Donoghue DP, Mulcahy HE, Ryan EJ, O'Sullivan JN. Tumour tissue microenvironment can inhibit dendritic cell maturation in colorectal cancer. PLoS One 2011, 6:e27944. 10.1371/journal.pone.0027944, 3220715, 22125641.